AccessibilityHelp
WuXi Biologics (Cayman) logo

WuXi Biologics (Cayman)(OTC) WXXWY

Market Cap$23.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+227%
5 Year-61%
1 Year+26%
1 Month-14%
$11.70
+1.30%
+0.15Today
WuXi Biologics (Cayman) last closing stock price
MetricPriceDate
Last closeUSD 11.702026-10-26
WuXi Biologics (Cayman) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.38%USD 12.242026-10-19
1 month-14.29%USD 13.652026-09-25
3 month+19.27%USD 9.812026-07-28
Year to date+46.25%USD 8.002025-12-31
1 year+25.52%USD 9.322025-10-24
3 year-1.68%USD 11.902023-10-27
5 year-61.16%USD 30.122021-10-27
Since inception+226.58%USD 3.542017-12-18

WuXi Biologics (Cayman) Financials at a Glance

Market Cap

$23.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥43.33B

Net Income (TTM)

CN¥9.13B

EPS (TTM)

$0.34

P/E Ratio

33.62

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$11.70

Volume

94,191

Open

$11.24

Previous Close

$11.70

Daily Range

$11.24 - $12.07

52-Week Range

$7.30 - $14.80

Estimated Earnings Date

Mar 23, 2027

WXXWY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a leading global provider of integrated solutions for biological drug development, encompassing the entire lifecycle from discovery to manufacturing. The company serves clients worldwide, with a strong presence in China, North America, and Europe.

Products and Services
  • Comprehensive biological drug development services
  • Contract development and manufacturing organization (CDMO) for vaccines
  • Advanced testing solutions and biopharmaceutical technology consulting
Growth Outlook
  • Revenue of CNY 11.66 billion in Q2 2026, showing consistent growth
  • Operating income margin of 31.6% indicates strong operational efficiency
  • Strategic partnerships with leading biotech firms enhance market position
Financial Highlights
  • Net income of CNY 2.41 billion in Q2 2026, reflecting robust profitability
  • Gross profit margin of 46.2% demonstrates effective cost management
  • Current ratio of 3.04 indicates strong liquidity and financial health
WuXi Biologics has established itself as a key player in the biotechnology sector, providing essential services that support the development of innovative therapies. The company's focus on integrated solutions allows it to cater to a diverse clientele, enhancing its competitive edge in the market. Recent financial performance highlights a strong revenue trajectory and profitability, positioning WuXi Biologics favorably for future growth. The strategic alliances with prominent partners further bolster its capabilities, ensuring continued relevance in the rapidly evolving biopharmaceutical landscape.
AI Generated • Oct 20, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

13,252

CEO

Zhi Sheng Chen, PhD

Website

www.wuxibiologics.com

Headquarters

Wuxi, JS 214092, CN

WXXWY Financials

Key Financial Metrics (TTM)

Gross Margin

47.47%

Operating Margin

32.36%

Net Income Margin

21.20%

Return on Equity

10.51%

Return on Capital

12.83%

Return on Assets

7.66%

Earnings Yield

2.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.04B

Volume

94.19K

Avg. Volume

63.54K

Financials (TTM)

Gross Profit

CN¥19.60B

Operating Income

CN¥13.42B

EBITDA

CN¥16.96B

Operating Cash Flow

CN¥13.23B

Capital Expenditure

-CN¥6.95B

Free Cash Flow

CN¥6.28B

Cash & ST Invst.

CN¥13.04B

Total Debt

CN¥2.73B

WuXi Biologics (Cayman) Performance Analysis

WuXi Biologics (Cayman) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,267,494,59642.1%
20232023-12-31CNY 2,404,260,5846.0%
20242024-12-31CNY 2,594,948,5077.9%
20252025-12-31CNY 3,031,254,84316.8%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3117.8%
Q22025-06-30-1.5%
Q42025-12-3116.7%
Q22026-06-300.3%
WuXi Biologics (Cayman) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.3026.3%
20232023-12-31CNY 0.22-27.3%
20242024-12-31CNY 0.220.0%
20252025-12-31CNY 0.3248.1%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3122.9%
Q22025-06-3027.9%
Q42025-12-317.3%
Q22026-06-30-1.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥11.66B

+36.0%

Gross Profit

CN¥5.39B

+60.8%

Gross Margin

46.22%

N/A

Market Cap

$23.87BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.80M

N/A

Employees

13,252

N/A

Net Income

CN¥2.41B

+61.0%

EBITDA

CN¥4.63B

+77.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥13.04B

+36.9%

Total Debt

CN¥2.73B

-40.3%

Accounts Receivable

CN¥8.59B

+39.0%

Inventory

CN¥1.82B

-7.1%

Long Term Debt

CN¥2.09B

-40.1%

Short Term Debt

CN¥641.58M

-40.9%

Return on Assets

7.66%

N/A

Return on Invested Capital

13.37%

N/A

Free Cash Flow

CN¥1.64B

+389.5%

Operating Cash Flow

CN¥4.46B

+242.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRLCharles River Laboratories International, Inc.
$357.27+3.45%
LZAGYLonza Group AG
$76.56+0.03%
WUXAYWuXi AppTec Co., Ltd.
$25.01+5.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$90.50+8.30%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.98-8.54%
TQQQProShares Trust - ProShares UltraPro Qqq
$68.43+3.23%
INTCIntel
$90.47+4.04%

Questions About WXXWY

What is the current price of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) is trading at $11.70 per share.

What is the 52-week range for WuXi Biologics (Cayman)?

Over the past 52 weeks, WuXi Biologics (Cayman) has traded between $7.30 and $14.80.

How much debt does WuXi Biologics (Cayman) have?

As of the most recent reporting period, WuXi Biologics (Cayman) reported total debt of CN¥444.19M.

How much cash does WuXi Biologics (Cayman) have on hand?

WuXi Biologics (Cayman) reported CN¥1.32B in cash and cash equivalents in its most recent financial results.

What is WuXi Biologics (Cayman)’s dividend yield?

WuXi Biologics (Cayman) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services